Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.

Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Liedke PE, Lang I, Elliott C, Gelmon KA, Chapman JA, Shepherd LE.

J Clin Oncol. 2013 Apr 10;31(11):1398-404. doi: 10.1200/JCO.2012.44.7805. Epub 2013 Jan 28.

2.
3.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

4.
5.
6.

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.

Riemsma R, Forbes CA, Kessels A, Lykopoulos K, Amonkar MM, Rea DW, Kleijnen J.

Breast Cancer Res Treat. 2010 Aug;123(1):9-24. doi: 10.1007/s10549-010-0974-0. Epub 2010 Jun 10. Review.

PMID:
20535542
7.
8.

The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.

Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G.

Cancer. 2004 Oct 1;101(7):1482-9. Review.

9.

[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].

van Nes JG, Seynaeve C, van de Velde CJ, Nortier JW.

Ned Tijdschr Geneeskd. 2006 Dec 30;150(52):2863-9. Review. Dutch.

PMID:
17319217
10.
11.

Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.

Glück S.

Am J Clin Oncol. 2010 Jun;33(3):314-9. doi: 10.1097/COC.0b013e31819fdf9b. Review.

PMID:
19730353
12.

Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.

Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI.

Cancer Treat Rev. 2008 Apr;34(2):157-74. doi: 10.1016/j.ctrv.2007.11.001. Epub 2007 Dec 31. Review.

PMID:
18164821
13.

Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.

Michaud LB.

Am J Health Syst Pharm. 2005 Feb 1;62(3):266-73. Review.

PMID:
15719584
14.

Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?

Geisler J.

Br J Cancer. 2011 Mar 29;104(7):1059-66. doi: 10.1038/bjc.2011.58. Epub 2011 Mar 1. Review.

15.
16.

Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.

Aapro MS, Forbes JF.

Breast Cancer Res Treat. 2003;80 Suppl 1:S3-11; discussion S13-8. Review.

PMID:
14535530
17.

Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.

Scott LJ, Keam SJ.

Drugs. 2006;66(3):353-62. Review.

PMID:
16526826
18.

Aromatase inhibitors in early breast cancer therapy.

Smith IE.

Semin Oncol. 2004 Dec;31(6 Suppl 12):9-14. Review.

PMID:
15719596
19.

The role of aromatase inhibitors in the treatment of metastatic breast cancer.

Mouridsen H, Gershanovich M.

Semin Oncol. 2003 Aug;30(4 Suppl 14):33-45. Review.

PMID:
14513435
20.

Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.

Glück S, Gorouhi F.

Am J Health Syst Pharm. 2011 Sep 15;68(18):1699-706. doi: 10.2146/ajhp100492. Review.

PMID:
21880884

Supplemental Content

Support Center